Pancreatic Cancer Research

ResearcherGeorgetown UniversityActive in the last 2 years

Benjamin Adam Weinberg

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-0408-4817; OpenAlex author ID A5055915497. Sources: ClinicalTrials.gov.

Their work

Papers
15 (first author 0, last author 3)
Trials
3 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
59
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 trial · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper, 1 trial · 2024: 4 papers, 1 trial · 2025: 2 papers · 2026: 1 paper

Papers 15

  1. Vascular Resection, Reconstruction, and Divestment in Pancreatoduodenectomy: Expanding Boundaries in Pancreatic Cancer Surgery. Co-author DOI 10.3390/cancers18040577↗
  2. A Review of Circulating Tumor DNA (ctDNA) in Pancreatic Cancer: Ready for the Clinic? Last author DOI 10.1007/s12029-024-01151-2↗
  3. Obesity reprograms the normal pancreas and pancreatic cancer microbiome in mice and humans. Co-author DOI 10.3389/frmbi.2025.1543144↗
  4. Patterns of Failure Following Preoperative Chemotherapy and Stereotactic Body Radiation Therapy and Resection for Patients with Borderline Resectable or Locall… Co-author DOI 10.1007/s12029-023-00996-3↗
  5. Phase 1 Study of Hypofractionated Proton Beam Radiation Therapy in Adjuvant Pancreatic Cancer (PROTON-PANC). Co-author DOI 10.1016/j.ijrobp.2023.09.015↗
  6. Comparative molecular profiling of pancreatic ductal adenocarcinoma of the head versus body and tail. Last author DOI 10.1038/s41698-024-00571-4↗
  7. Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-1164↗
  8. Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic revi… Last author DOI 10.1016/j.suronc.2023.102007↗
  9. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-3581↗
  10. Cholecystokinin Receptor Antagonist Improves Efficacy of Chemotherapy in Murine Models of Pancreatic Cancer by Altering the Tumor Microenvironment. Co-author DOI 10.3390/cancers13194949↗
  11. A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy. Co-author DOI 10.1089/pancan.2020.0005↗
  12. A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1301↗
  13. Evolving standards of care for resected pancreatic cancer. Co-author PMID 28398285↗
  14. Current Standards and Novel Treatment Options for Metastatic Pancreatic Adenocarcinoma. Co-author PMID 26573060↗
  15. Maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy: a retrospective cohort study. Co-author PMID 25276262↗

Trials 3

  1. Proglumide and Chemotherapy for Metastatic Pancreatic Cancer Principal investigator NCT05827055↗
  2. BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Study chair NCT05558982↗
  3. Study of Proton Therapy in Adjuvant Pancreatic Cancer Principal investigator NCT03885284↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. John Lindsay Marshall · 6 shared papers, 2014–2024 · strength 0.76
  2. Keith Robert Unger · 3 shared papers, 2024–2026 · strength 0.69
  3. Aiwu Ruth He · 5 shared papers, 2014–2024 · strength 0.64
  4. Michael Jon Pishvaian · 5 shared papers, 2014–2024 · strength 0.50
  5. Louis M. Weiner · 3 shared papers, 2020–2024 · strength 0.48
  6. Purvi Jonnalagadda · 1 shared paper, 2025 · strength 0.42
  7. Emily R. Winslow · 2 shared papers, 2024 · strength 0.37
  8. Marcus Smith Noel · 2 shared papers, 2024 · strength 0.37
  9. Yuri Genyk · 1 shared paper, 2026 · strength 0.32
  10. Dimitrios Moris · 1 shared paper, 2026 · strength 0.32
  11. David B. Spetzler · 2 shared papers, 2022–2024 · strength 0.27
  12. Sonia de Assis · 1 shared paper, 2025 · strength 0.27
  13. Raquel Santana da Cruz · 1 shared paper, 2025 · strength 0.27
  14. Nestor F. Esnaola · 1 shared paper, 2024 · strength 0.24
  15. Abdullah Esmail · 1 shared paper, 2024 · strength 0.24
  16. Maen Abdelrahim · 1 shared paper, 2024 · strength 0.24
  17. Anup Kasi · 1 shared paper, 2024 · strength 0.24
  18. Philip A. Philip · 2 shared papers, 2017–2022 · strength 0.23
  19. Reetu Mukherji · 1 shared paper, 2023 · strength 0.22
  20. Ali Jaber Alqahtani · 1 shared paper, 2023 · strength 0.22
  21. Chao Yin · 1 shared paper, 2023 · strength 0.22
  22. Jonathan Robert Brody · 2 shared papers, 2015–2020 · strength 0.18
  23. Nicole Libbey · 1 shared paper, 2024 · strength 0.18
  24. Jimmy J. Hwang · 2 shared papers, 2014–2020 · strength 0.15
  25. Harshabad Singh · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.